^
    Back
    Association details:
    Biomarker:ESR1 mutation
    Cancer:HER2 Negative Breast Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    SABCS 2023
    Title:

    Genomic-determinants-benefit-nivolumab-NIVO-dose-ipilimumab-IPI-patients-pts-hypermutated-HER2negative-metastatic-breast-cancer-MBC-results-NIMBUS-trial/CR

    Published date:
    12/02/2023
    Excerpt:
    ESR1 and PTEN mutations were associated with absence of PR while PALB2 was associated with objective response….Among the entire 29 pts, a negative correlation between PTEN with PFS and OS, and positive correlation between PALB2 with PFS was observed…In the NIMBUS trial, all pts with PR to NIVO plus low dose IPI had a TMB > 20 Mut/Mb and had a decrease in TMB during treatment. ESR1 and PTEN mutations were associated with lack of benefit, while PALB2 mutation was associated with increased benefit.